Nirmatrelvir (Paxlovid) Mini-HTA for the treatment of COVID-19.

Simple item page
dc.contributor.authorInstituto Global para la Excelencia en el Cuidado de la Salud Keralty
dc.date.accessioned2026-04-10T14:33:57Z
dc.date.available2026-04-10T14:33:57Z
dc.date.issued2022
dc.description.abstractCOVID-19 antiviral treatments are still in the early stages of development, considering that the disease was first identified in late 2019. COVID-19 nirmatrelvir is recommended for use in patients older than 12 years and weighing more than 40 kilograms with risk factors for moderate COVID-19 and who already have a positive COVID-19 test. The risks of using nirmatrelvir appear to be lower than the potential benefits.
dc.formattext
dc.identifier.urihttps://repositorio.unisanitas.edu.co/handle/123456789/1173
dc.language.isoen
dc.publisherKeralty
dc.titleNirmatrelvir (Paxlovid) Mini-HTA for the treatment of COVID-19.
dc.typeDocumento
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ETES MiniHTA Nirmatrelvir COVID19 IH 050122 Ingles.pdf
Size:
1.14 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.15 KB
Format:
Item-specific license agreed to upon submission
Description:
Download
Collections
Evaluaciones de tecnología sanitaria